Member Directory
Carocell Bio are developing novel peptides to more safely and effectively treat inflammatory diseases.
Catalent, Inc. is a global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,500 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply approximately 70 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of nearly 18,000 includes more than 3,000 scientists and technicians.
Point of contact:
Peter F. Farmer, Senior Account Director
Peter.Farmer@catalent.com
Linkedin: https://www.linkedin.com/in/peter-farmer-62843513/
Discovery services in oncology, immunology and respiratory
CPI provides assets and resources to support innovations in the manufacture of biologics. Utilising our state of the art facilities and technical expertise, we help our clients to de-risk process development through proof of concept testing to accelerate the commercialisation of new processes and technologies. . . Our skilled team of scientists, engineers and sector specialists can help companies of all sizes to develop, demonstrate, prototype and scale-up innovations that could be beneficial to biologics manufacture and provision. From initial programme scoping and planning through to process demonstration and scale-up we have a range of services which can be tailored to meet your needs. . . Collaboration with CPI will enable the biologics industry to capitalise on its strong research and development pipeline and make more therapies available for unmet clinical needs. We support the commercialisation of research by promoting collaboration with industry across the supply chain from research through to manufacture and clinic.
Cerevance is a new pharmaceutical company focused on central nervous system diseases. Our strengths include a powerful technology platform, a pipeline of novel discovery-stage and clinical-stage compounds, and a proven team. We believe that we are well positioned to deliver life-changing therapeutics for patients who have brain-related disorders, while creating value for our employees and shareholders.
CFGI is an international, non-audit, accounting advisory firm free of auditor independence restrictions. Consisting of ex-Big4 professionals, CFGI is strategically positioned to help companies and private equity sponsors through a range of routine and complex business scenarios.
Founded in the US in 2000, and now operating across the UK, CFGI is ideally placed to support companies throughout their lifecycle, from ambitious high growth pre-revenue start-ups, right through to established, commercial public companies. CFGI has expertise across a wide range of sectors, with a particular specialism in Lifesciences and Healthcare.
Operating as a hands-on extension of your finance team, CFGI works alongside your people, serving in a variety of roles – from technical accounting advisor to M&A support, to IPO readiness to listed company financial reporting – and delivering seamless support services. Without the independence restrictions of an audit practice, CFGI’s model allows for a rapid, flexible and cost competitive response to deliver a tailored solution for each challenge encountered.
The range of areas of support include:
» Technical accounting
» IPO readiness and support
» Interim management
» Valuation
» Audit assistance
» Cybersecurity
» Risk advisory and controls
» Transaction services
» ESG implementation
» Financial reporting
» Business transformation
» Tax services
Contact Paul Cooper our UK Healthcare and Lifesciences lead at pcooper@cfgi.com
Near the end of 2020, Deepmind announced that they had solved of the protein folding problem, a "50-year-old grand challenge in biology". Their approach was end-to-end deep learning, and it was the first time deep learning had solved an important scientific problem.
We believe this along with other recent breakthroughs in deep learning on 3D molecular configurations are the start of a new era in drug discovery, akin to the what AlexNet did for computer vision in 2012. Inspired by these breakthroughs, **CHARM Therapeutics** was founded with the mission to harness the power of deep learning to deliver medicines of transformational efficacy for patients.